<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Karayal, Onur</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ziprasidone as Adjunct Therapy to Mood Stabilizers for the Treatment of Bipolar I Disorder</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">When used as adjunctive treatment to the mood stabilizers lithium or valproate, ziprasidone was equally effective in stabilizing mild to moderately ill subjects and severely ill subjects with bipolar I disorder (BP I). In a Phase III, randomized, double-blind, placebo-controlled trial that evaluated the efficacy of adjunct ziprasidone therapy with a mood stabilizer in the long-term maintenance treatment of BP I, patients were stratified according to baseline illness severity (as determined by Mania Rating Scale score).</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>